COMMUNIQUÉS West-GlobeNewswire
-
NextCure Receives Fast Track Designation for SIM0505 (CDH6 ADC) in Ovarian Cancer
07/04/2026 -
CorMedix to Participate in Needham Virtual Healthcare Conference
07/04/2026 -
Amneal Announces $2 Million Donation to Support Patient Access to Essential Medicines During Parkinson’s Awareness Month
07/04/2026 -
Valitor Announces Oral Presentation at the Upcoming Association for Research in Vision and Ophthalmology (ARVO) 2026 Annual Meeting
07/04/2026 -
Solid Biosciences to Participate at Upcoming Investor Conferences
07/04/2026 -
Calidi Biotherapeutics Announces Speaker Presentation at ASGCT Conference in Boston on May 14, 2026 Highlighting the RedTail Platform’s Ability to Deliver Genetic Medicines to Distal Sites of Disease with Systemic Therapy
07/04/2026 -
NTG Nordic Transport Group A/S - Q1 2026 Conference Call
07/04/2026 -
Emergent BioSolutions Launches New NARCAN® Nasal Spray Carrying Case and Multipacks Alongside College Campus Outreach to Expand Opioid Overdose Preparedness
07/04/2026 -
Akebia Therapeutics to Conduct Investor Meetings at the Raymond James 2026 Biotech Innovation Symposium
07/04/2026 -
Moleculin Releases Next CEO Corner Segment Highlighting Annamycin’s Non-Cardiotoxic Profile
07/04/2026 -
CDT Notes Sarborg Publication of PRISM Framework Expanding AI
07/04/2026 -
Inhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertension
07/04/2026 -
SS Innovations to Host SMRSC 2026 in New Delhi, India from April 9-11, 2026
07/04/2026 -
Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference
07/04/2026 -
Cognition Therapeutics to Present at Needham Virtual Healthcare Conference
07/04/2026 -
Abeona Therapeutics® Announces Appointment of Keith A. Goldan to its Board of Directors
07/04/2026 -
Lyell Immunopharma Announces Participation in 25th Annual Needham Virtual Healthcare Conference
07/04/2026 -
Outlook Therapeutics Announces Formal Dispute Resolution Request for ONS-5010/LYTENAVA™ (bevacizumab-vikg) Accepted by FDA
07/04/2026 -
Marvel Biosciences Secures Financial and Strategic Investment with 5 Horizon Ventures
07/04/2026
Pages